ly 353381 has been researched along with ospemifene in 2 studies
| Studies (ly 353381) | Trials (ly 353381) | Recent Studies (post-2010) (ly 353381) | Studies (ospemifene) | Trials (ospemifene) | Recent Studies (post-2010) (ospemifene) |
|---|---|---|---|---|---|
| 70 | 12 | 15 | 147 | 30 | 114 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lewiecki, EM | 1 |
| Chines, AA; Komm, BS | 1 |
2 review(s) available for ly 353381 and ospemifene
| Article | Year |
|---|---|
Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Drug Therapy, Combination; Female; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Piperidines; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Vitamin D; Women's Health | 2009 |
An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis.
Topics: Bone Density Conservation Agents; Breast; Endometrium; Female; Fractures, Bone; Humans; Indoles; Osteoporosis, Postmenopausal; Piperidines; Pyrrolidines; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes | 2012 |